Pharma News

The incident sheds light on a broader problem in the manufacturing of popular drugs: fake drug lot numbers.

The Chinese government has announced that it will allow wholly foreign-owned hospitals to be set up in nine regions, including Beijing, in a bid to attract foreign investment and stimulate the economy to boost the flagging economy.

Amir Malik, Pfizer's Chief Commercial Officer in the United States, stressed that the launch of the platform is an important step in the company's commitment to simplifying access to health care for people seeking a better and healthier life.

Novartis has entered into a licensing and collaboration agreement with Lindy Biosciences to further optimize the delivery of biologics.

Global pharmaceutical industry leader Eli Lilly has entered into a research collaboration agreement with Genetic Leap, an upstart drug developer powered by artificial intelligence, confirmed authoritative sources.

Thanks to the market success of its two weight-loss drugs, Mounjaro and zepbound, Lilly's market value has steadily climbed to about $855 billion.

Japan's Kirin Holdings has amassed enough equity to complete its takeover of health supplement maker Fancl, the company's new president has announced.

On September 3, Vaxcyte announced results from a direct comparison of its 31-valent pneumococcal conjugate vaccine, VAX-31, with Pfizer Prevnar 20.

Roche announced on September 4 the latest results from the Phase II FENopta Open Label Extension (OLE) study of the BTK inhibitor fenebrutinib.

The company has successfully acquired Saiba Animal Health (SAH), a company dedicated to the development of therapeutic vaccines aimed at addressing an unmet need in the field of veterinary medicine.

Pasil auxin injection contains the active ingredient somapacitan, which is a long-acting variant of human growth hormone (hGH). Somapacitan modifies natural hGH and enhances its affinity with plasma albumin, thus adapting to a weekly dosing regimen.

Olon continues its growth momentum and increases its total production capacity with the acquisition of Huvepharma Italia and its plant in Garessio, Cuneo, in northwestern Italy.

• Olon
• Huvepharma Italia

Vientumab is indicated for the treatment of locally advanced or metastatic uroepithelial carcinoma in adult patients who have previously received platinum-containing chemotherapy and programmed death receptor-1 or programmed death ligand-1 inhinitors.

Despite this challenge, the company's positive expectations for GLP-1 pharmaceutical contracts will provide strong support for future profit growth. At the close of trading, shares in Aspen Pharmacare slipped, falling 13.23 per cent to close at R213.60.

Pfizer recently announced that it has completed the acquisition of Seagen, which specializes in antibody drug coupling agents (ADCs), for $43 billion.

Pharmaceutical giant Mundipharma International, part of the world-renowned Sackler Family, has failed for the second time to find a suitable buyer for its China unit in an asset disposal process restarted this year.

The Indonesian president on Monday announced his country's intention to sign commercial contracts totaling $3.5 billion with African countries during the second Indonesia-Africa Forum in Bali.

Under the agreement, the two companies will jointly develop two small molecule therapies targeting long non-coding Rnas (lncrnas), with the aim of further strengthening Bayer's R&D pipeline in precision oncology.

On August 30, HUTCHMED officially announced that it had voluntarily withdrawn its marketing application for fuquinitinib for second-line gastric cancer.

UCB, a Belgian-based biopharmaceutical company, will sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and Abu Dhabi-based investment company Mubadala for US$680 million (about 4.843 billion yuan).

• UCB